179 related articles for article (PubMed ID: 36388025)
1. Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic
Zheng W; Niu N; Zeng J; Ke X; Jin S
Transl Cancer Res; 2022 Oct; 11(10):3895-3902. PubMed ID: 36388025
[TBL] [Abstract][Full Text] [Related]
2. Two case reports of non-small cell lung cancer patients harboring acquired
Song Z; Ren G; Hu L; Wang X; Song J; Jia Y; Zhao G; Zang A; Du H; Sun Y; Zhao X
Ann Transl Med; 2022 Jun; 10(12):719. PubMed ID: 35845537
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
Li X; Zhang D; Li B; Zou B; Wang S; Fan B; Li W; Yu J; Wang L
Lung Cancer; 2021 Jan; 151():39-43. PubMed ID: 33296806
[TBL] [Abstract][Full Text] [Related]
4. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
5. BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
Li X; Wang S; Li B; Wang Z; Shang S; Shao Y; Sun X; Wang L
Target Oncol; 2018 Aug; 13(4):517-523. PubMed ID: 29907952
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase 3 Inhibition Overcomes
Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
[No Abstract] [Full Text] [Related]
7. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations.
Xu H; Li W; Yang G; Li J; Yang L; Xu F; Yang Y; Ying J; Wang Y
Target Oncol; 2020 Jun; 15(3):357-364. PubMed ID: 32418166
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib in uncommon
Wang Y; Dorwal P; Rajadurai S; Arulananda S
Transl Lung Cancer Res; 2024 Feb; 13(2):434-442. PubMed ID: 38496692
[TBL] [Abstract][Full Text] [Related]
10.
Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel
Zhi X; Luo J; Li W; Wang J; Wang Y; Cai Y; Yan X
Front Oncol; 2021; 11():733276. PubMed ID: 34760695
[TBL] [Abstract][Full Text] [Related]
12. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
[TBL] [Abstract][Full Text] [Related]
13. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
[TBL] [Abstract][Full Text] [Related]
14. Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer.
Isobe K; Yoshizawa T; Sekiya M; Miyoshi S; Nakamura Y; Urabe N; Isshiki T; Sakamoto S; Takai Y; Tomida T; Adachi-Akahane S; Iyoda A; Homma S; Kishi K
Respir Investig; 2021 Jul; 59(4):535-544. PubMed ID: 33934994
[TBL] [Abstract][Full Text] [Related]
15. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.
Zou Q; Zhan P; Lv T; Song Y
Transl Lung Cancer Res; 2015 Dec; 4(6):792-6. PubMed ID: 26798589
[TBL] [Abstract][Full Text] [Related]
16. Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Xia J; Bai H; Yan B; Li R; Shao M; Xiong L; Han B
Oncotarget; 2017 Dec; 8(65):108522-108533. PubMed ID: 29312548
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.
Shen Q; Qu J; Chen Z; Zhou J
Front Oncol; 2021; 11():760097. PubMed ID: 34926262
[TBL] [Abstract][Full Text] [Related]
18. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
19. Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report.
Chen J; Zhao X; Wang J; Liu F; Zhang L; Chen Y; Chu Q
Transl Cancer Res; 2022 Sep; 11(9):3343-3348. PubMed ID: 36237272
[TBL] [Abstract][Full Text] [Related]
20. Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.
Wang JL; Wang LS; Zhu JQ; Ren J; Wang D; Luo M
Respirol Case Rep; 2022 Nov; 10(11):e01054. PubMed ID: 36258694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
